Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
May 18, 2022

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

May 12, 2022

-- Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET -- TEL AVIV, Israel, May 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage...

May 4, 2022

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Mar 23, 2022

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

All News

Stock Info
NASDAQCMMB
Events
Monday, June 13, 2022 - Thursday, June 16, 2022

In person in San Diego, California
Chemomab is participating in BIO’s One-on-One Partnering™
Explore partnering opportunities with Chemomab’s business development team
Partnering registration

Monday, May 23, 2022 - Thursday, May 26, 2022

Date: Chemomab webcast available on demand starting at 7:00am ET May 24 – May 26, 2022
Replay: Available at Chemomab website at investors.chemomab.com/events
Information: hcwevents.com/globalconference/.

All Events

Featured Presentations

Download

Chemomab Corporate Overview - May 2022

 

Annual Report

Download

Chemomab 2021 Annual Report